Are SLC30A8, CDKN2A/CDKN2B, KCNJ11, and MTNR1B risk genotypes linked to type 2 diabetes?

Clinical evidence

• Genotype-specific T2D risk: Large-scale genome-wide association studies (GWAS) and meta-analyses consistently link specific risk genotypes of SLC30A8 (rs13266634 CC), CDKN2A/CDKN2B (rs10811661 TT), KCNJ11 (rs5219 CT), and MTNR1B (rs10830963 CG) with elevated susceptibility to type 2 diabetes (T2D).
• Quantifiable genetic risk:
  • For SLC30A8 rs13266634, the CC genotype increases T2D risk by approximately 33% compared to TT, carrying a per-allele odds ratio (OR) of 1.14–1.15.
  • The CDKN2A/CDKN2B rs10811661 TT genotype acts additively, presenting one of the strongest common-variant signals with a per-allele OR of 1.21–1.27.
  • For KCNJ11 rs5219, the CT (EK heterozygote) genotype increases susceptibility with a modest OR of approximately 1.09 (while homozygous KK risk carriers show a 26–27% risk increase).
  • The MTNR1B rs10830963 CG genotype raises risk with a per-allele OR of approximately 1.09.

Mechanistic explanations

• Convergent beta-cell dysfunction: These genetic variations drive diabetes susceptibility through distinct but convergent molecular pathways that reduce pancreatic beta-cell function (quantified via HOMA-B) and compromise insulin secretion.
• Distinct pathways of secretory impairment:
  • KCNJ11 (rs5219): Alters ATP-sensitive potassium ($K_{ATP}$) channel gating properties, which prevents normal cell membrane depolarization and impairs the exocytosis of insulin granules.
  • MTNR1B (rs10830963): Elevates melatonin receptor expression on pancreatic islets, enhancing melatonin-mediated signaling which directly blunts early-phase, glucose-stimulated insulin secretion.
  • SLC30A8 (rs13266634): Disrupts ZnT8 zinc transporter activity, impairing zinc transport into secretory granules. This limits insulin hexamer crystallization and compromises the physical storage and release of insulin.
  • CDKN2A/CDKN2B (rs10811661): Acts as a negative regulator of exocytotic competence, curtailing secretory efficiency independently of its role in cell-cycle inhibition.

Clinical implications

• Impaired fasting glycemia: The downstream physiological effect of these combined secretagogue impairments is elevated fasting plasma glucose levels.
• Disrupted glucose homeostasis: MTNR1B and KCNJ11 act as particularly prominent drivers of fasting hyperglycemia, preventing the dynamic pancreatic beta-cell compensation required to maintain basal glucose homeostasis overnight and during fasting states.

Bottom line

The specific genotypes of SLC30A8 (rs13266634 CC), CDKN2A/CDKN2B (rs10811661 TT), KCNJ11 (rs5219 CT), and MTNR1B (rs10830963 CG) are robustly associated with an increased risk of type 2 diabetes. They collectively drive disease susceptibility through distinct molecular mechanisms that impair pancreatic beta-cell function, limit insulin exocytosis, and elevate fasting plasma glucose levels.